港股创新药ETF（159567）涨超0.5%，荣昌生物涨超3%，机构：坚定看好创新药的出海前景

Group 1 - The Hong Kong stock market opened with the Hang Seng Index rising by 0.9% and the Hang Seng Tech Index increasing by 1.58%, indicating a positive market sentiment towards innovative pharmaceuticals [1] - The Hong Kong Innovative Drug ETF (159567) showed active trading with a turnover exceeding 85 million yuan and a trading volume increase of 0.51%, reflecting strong investor interest [1] - Major stocks in the innovative drug sector, such as Rongchang Biopharmaceutical and China Biologic Products, saw significant gains, with increases of over 3% and 2% respectively [1] Group 2 - Huayuan Securities reported that innovative drug companies are projected to achieve revenues of 47.53 billion yuan in 2024, marking a year-on-year growth of 68.4%, indicating a robust growth trend [2] - Domestic innovative drug companies have largely completed their R&D cycles, with core products entering a phase of rapid commercialization, leading to accelerated revenue growth [2] - The trend of overseas licensing has emerged as a second growth curve for biotech companies, providing sustainable funding support for ongoing R&D through high upfront payments [2]